SML2159
Minodronic acid monohydrate
≥98% (HPLC)
Synonym(s):
[1-Hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethylidene]bisphosphonic acid monohydrate
Sign Into View Organizational & Contract Pricing
Select a Size
About This Item
Empirical Formula (Hill Notation):
C9H12N2O7P2 · H2O
CAS Number:
Molecular Weight:
340.16
MDL number:
UNSPSC Code:
12352106
NACRES:
NA.77
Assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
0.1 M NaOH: 2 mg/mL, clear (warmed)
storage temp.
2-8°C
SMILES string
OC(P(O)(O)=O)(P(O)(O)=O)CC1=CN=C2N1C=CC=C2.O
InChI
1S/C9H12N2O7P2.H2O/c12-9(19(13,14)15,20(16,17)18)5-7-6-10-8-3-1-2-4-11(7)8;/h1-4,6,12H,5H2,(H2,13,14,15)(H2,16,17,18);1H2
InChI key
GPAPAOGRNKUFGH-UHFFFAOYSA-N
Related Categories
Biochem/physiol Actions
Bone resorption inhibitor; inhibitor of farnesyl diphosphate synthase
Minodronate is a third-generation bisphosphonate used clinically alone or in combination to treat osteoporosis. It is an inhibitor of farnesyl diphosphate synthase that acts as a bone resorption inhibitor.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Shinichi Nakatoh
Journal of bone and mineral metabolism, 36(2), 221-228 (2017-03-16)
This study reveals the changes in bone mineral density (BMD), the turnover rate, and the balance [multiple of median formation/multiple of median resorption (MoMf/MoMr)] affected by the selection of different bone resorption inhibitors after 24-month daily teriparatide (20 µg/day) administration.
Motoaki Yasukawa et al.
Anticancer research, 36(11), 5883-5886 (2016-10-30)
Non-small cell lung carcinoma (NSCLC) is one of the leading causes of cancer-related death worldwide. Recent studies showed that nitrogen-containing bisphosphonates (N-BPs) directly and indirectly prevent proliferation, induce apoptosis, and inhibit metastasis of various types of cancer cell. In order
Tsuyoshi Ohishi et al.
Endocrine research, 42(3), 232-240 (2017-03-21)
Monthly regimen of minodronate for osteoporosis more than two years has not been reported yet. The aim of this study is to elucidate the effect of monthly minodronate (M-MIN) on bone mineral density (BMD) and serum pentosidine (Pen) during 27
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service